313 related articles for article (PubMed ID: 26345314)
21. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
[TBL] [Abstract][Full Text] [Related]
22. Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Mistry PK; Balwani M; Baris HN; Turkia HB; Burrow TA; Charrow J; Cox GF; Danda S; Dragosky M; Drelichman G; El-Beshlawy A; Fraga C; Freisens S; Gaemers S; Hadjiev E; Kishnani PS; Lukina E; Maison-Blanche P; Martins AM; Pastores G; Petakov M; Peterschmitt MJ; Rosenbaum H; Rosenbloom B; Underhill LH; Cox TM
Blood Cells Mol Dis; 2019 Jul; 77():101-102. PubMed ID: 31029022
[No Abstract] [Full Text] [Related]
23. Carcinogenicity testing of eliglustat in mice and rats.
Dagher R; Watzinger M; Chevalier G; Thirion-Delalande C; Gervais F; Forster R
Regul Toxicol Pharmacol; 2015 Oct; 73(1):401-12. PubMed ID: 26232705
[TBL] [Abstract][Full Text] [Related]
24. Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy.
Kim YM; Shin DH; Park SB; Cheon CK; Yoo HW
BMC Med Genet; 2017 May; 18(1):55. PubMed ID: 28506293
[TBL] [Abstract][Full Text] [Related]
25. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
26. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
[TBL] [Abstract][Full Text] [Related]
27. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Goker-Alpan O; Watman N; El-Beshlawy A; Kishnani PS; Pedroso ML; Gaemers SJM; Tayag R; Peterschmitt MJ
Blood; 2017 Apr; 129(17):2375-2383. PubMed ID: 28167660
[TBL] [Abstract][Full Text] [Related]
28. How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.
Ruskin JN; Ortemann-Renon C; Msihid J; Ross L; Puga AC; Peterschmitt MJ; Cox GF; Maison-Blanche P
Mol Genet Metab; 2020; 131(1-2):211-218. PubMed ID: 33012655
[TBL] [Abstract][Full Text] [Related]
29. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Peterschmitt MJ; Freisens S; Underhill LH; Foster MC; Lewis G; Gaemers SJM
Orphanet J Rare Dis; 2019 Jun; 14(1):128. PubMed ID: 31174576
[TBL] [Abstract][Full Text] [Related]
30. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.
Lukina E; Watman N; Arreguin EA; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Kamath RS; Rosenthal DI; Kaper M; Singh T; Puga AC; Peterschmitt MJ
Blood; 2010 Nov; 116(20):4095-8. PubMed ID: 20713962
[TBL] [Abstract][Full Text] [Related]
31. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
Wilson MW; Shu L; Hinkovska-Galcheva V; Jin Y; Rajeswaran W; Abe A; Zhao T; Luo R; Wang L; Wen B; Liou B; Fannin V; Sun D; Sun Y; Shayman JA; Larsen SD
ACS Chem Neurosci; 2020 Oct; 11(20):3464-3473. PubMed ID: 33035424
[TBL] [Abstract][Full Text] [Related]
32. Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat.
Harai N; Ichijo M; Uchinuma H; Hanihara M; Kawaguchi Y; Ichikawa D; Tsuchiya K
Intern Med; 2023 Oct; 62(20):3005-3011. PubMed ID: 36889706
[TBL] [Abstract][Full Text] [Related]
33. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?
Shayman JA
Trans Am Clin Climatol Assoc; 2013; 124():46-60. PubMed ID: 23874009
[TBL] [Abstract][Full Text] [Related]
34. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
Peterschmitt MJ; Foster MC; Ji AJ; Zajdel MB; Cox GF
Mol Genet Metab; 2023 Mar; 138(3):107527. PubMed ID: 36739645
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
36. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.
Kamath RS; Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Aguzzi R; Puga AC; Norfleet AM; Peterschmitt MJ; Rosenthal DI
Skeletal Radiol; 2014 Oct; 43(10):1353-60. PubMed ID: 24816856
[TBL] [Abstract][Full Text] [Related]
37. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses C
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
[TBL] [Abstract][Full Text] [Related]
38. Long-term eliglustat treatment of Gaucher patients over up to 10 years in Vienna.
Stulnig TM
Wien Klin Wochenschr; 2022 Jun; 134(11-12):471-477. PubMed ID: 35412052
[TBL] [Abstract][Full Text] [Related]
39. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]